Product Information

OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $1.1082 per EA under NDC 70436001504. Its NADAC has been published 29 times since Feb 4, 2026.

FDA first approved this application on May 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5

olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide
$1.1082per EA

Strength

5; 12.5; 40 mg/1; mg/1; mg/1

NDC

70436001504

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA210718

FDA Approved

5/14/2025

TE Code

AB

On Market Since

5/15/2025

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Dihydropyridine Calcium Channel Blocker
Dihydropyridines
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 has been published 29 times since Feb 4, 2026, and over the history we have for it it has declined 16.1%. The table below summarizes its recorded NADAC range and movement.

Current price$1.1082 per EA
All-time high$1.3200 (Feb 11, 2026)
All-time low$1.1082 (Aug 19, 2026)
52-week high$1.3200
52-week low$1.1082
Median price$1.1884
Average price$1.1799
Largest weekly change-10.0% (Feb 18, 2026)
Weeks tracked29
Tracking sinceFeb 4, 2026

Price History

1W

-0.8%

1M

-0.8%

3M

-9.9%

6M

-6.7%

1Y

N/A

3Y

N/A

5Y

N/A

All

-16.1%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?

The current National Average Drug Acquisition Cost (NADAC) for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5, manufactured by Slate Run Pharmaceuticals LLC, is $1.1082 per EA (NDC 70436001504), effective Aug 19, 2026.

How has the price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 changed over time?

Over the history we have for it, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 has declined 16.1%. It has been tracked across 29 weekly CMS publications since Feb 4, 2026.

What are the highest and lowest recorded NADAC prices for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?

Since Feb 4, 2026, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 has ranged from a low of $1.1082 (Aug 19, 2026) to a high of $1.3200 (Feb 11, 2026), with a median of $1.1884 per EA.

Are there cheaper alternatives to OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?

No other NADAC-published product currently shares the active ingredient and strength of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?

OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 (NDC 70436001504) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.